Thermo and Biognosys Announce Co-Marketing Agreement
News Jun 09, 2017
Partnership to provide a comprehensive, efficient workflow to enable library creation and data processing for Data-Independent Acquisition (DIA) studies, through the combined use of Orbitrap mass spectrometers and Spectronaut Pulsar software.
Compatible with the new Thermo Scientific Q Exactive HF-X Hybrid Quadrupole Orbitrap mass spectrometer, in addition to previous Orbitrap instruments, the Biognosys Spectronaut Pulsar software allows researchers to conduct data-independent analysis using MS1 quantitation for reproducible and accurate quantitation of thousands of proteins in a single run. DIA is a global method for the comprehensive recording of spectral signatures from all components of a sample, and can be used in combination with the latest high-resolution Orbitrap instruments as a universal method for global expression profiling.
“DIA is part of our quantitative proteomics arsenal. It is it an excellent fit for discovery proteomics, providing both high depth of proteome coverage in large sample series and the ability to reproduce data points more precisely between technical replicates than other methods. As such, it complements other quantitative techniques such as Tandem Mass Tags (TMT) and Parallel Reaction Monitoring (PRM),” said Andreas Huhmer, director, proteomics and metabolomics marketing, chromatography and mass spectrometry, Thermo Fisher. “The Spectronaut Pulsar software creates an efficient pipeline for spectral library creation and processing of large DIA datasets.”
“We developed Spectronaut Pulsar to support our own contract DIA services business, as well as our research customers with access to high-resolution instruments,” said Lukas Reiter, chief technology officer, Biognosys. “It has been extensively optimized to take advantage of HRAM data from Orbitrap mass spectrometers as this is the platform we work on ourselves. Spectronaut Pulsar is easy to use, very fast and able to process very large datasets and every detail was optimized to provide the best possible quantitative results.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Microscopy Technique Could Enable More Informative BiopsiesNews
MIT and Harvard Medical School researchers have devised a way to image biopsy samples with much higher resolution — an advance that could help doctors develop more accurate and inexpensive diagnostic tests.READ MORE
Comments | 0 ADD COMMENT
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018
EMBL Course: Introduction to Metabolomics Analysis
Mar 20 - Mar 23, 2018
EMBL Course: RNA Sequencing Library Preparation - How Low Can You Go?
Mar 19 - Mar 23, 2018
EMBL Course: Analysis and Integration of Transcriptome and Proteome Data
Mar 12 - Mar 16, 2018